Real-time analysis of dopamine: antagonist interactions at recombinant human D2long receptor upon modulation of its activation state.
1. Antipsychotic drugs may mediate their therapeutic effects not only by preventing the binding of dopamine but also by decreasing the propensity of the dopamine receptor to assume an active R* state. Ligand-mediated activation and blockade of the recombinant human D(2long) receptor was investigated in CHO-K1 cells upon modulation of its R* state. 2. Both the Ala(371)Lys (A371K) and Thr(372)Arg (T372R) D2long receptor mutants could be activated in a ligand-dependent manner via a chimeric G(alphaq/o) protein, and more efficaciously so than with the promiscuous G(alpha15) protein. 3. Dopamine and partial agonists (E(max): lisuride >> (+)-UH 232 approximately bromerguride) displayed dissimilar Ca(2+) kinetic properties at wild-type and mutant receptors. A371K and T372R D2long receptor mutants demonstrated an attenuated and enhanced maximal response to these partial agonists, respectively. 4. Dopamine antagonists were unable to block the transient high-magnitude Ca(2+) phase at the wild-type D2long receptor upon simultaneous exposure to antagonist and dopamine, while full blockade of the low-magnitude Ca(2+) phase did occur at a later time (onset-time: haloperidol < bromerguride < (+)-butaclamol). A similar, though more efficacious, antagonist profile was also found at the A371K mutant receptor. Conversely, the blockade of the low-magnitude Ca(2+) phase was attenuated (haloperidol) or almost absent [(+)-butaclamol and bromerguride] at the T372R mutant receptor. 5. In conclusion, mutagenesis of the Ala(371) and Thr(372) positions affects in an opposite way the ligand-dependent activation and blockade of the D2long receptor. The observed attenuation of dopamine-mediated Ca(2+) signal generation with different decay-times may underlie distinct properties of the dopaminergic ligands.
Pauwels
P J
PJ
Department of Cellular and Molecular Biology, Centre de Recherche Pierre Fabre, 17, avenue Jean Moulin, 81106 Castres Cédex, France. peter.pauwels@pierre-fabre.com
Tardif
S
S
Wurch
T
T
Colpaert
F C
FC
D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000031:analogs & derivatives* / Q000494:pharmacology; D017398:Alternative Splicing; D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D002069:Butaclamol / Q000494:pharmacology; D016466:CHO Cells; D002118:Calcium / Q000378:metabolism; D003024:Clozapine / Q000494:pharmacology; D006224:Cricetinae; D004298:Dopamine / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000378:metabolism* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005838:Genotype; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000378:metabolism; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D008090:Lisuride / Q000031:analogs & derivatives* / Q000494:pharmacology; D009154:Mutation; D010957:Plasmids / Q000235:genetics; D011954:Receptors, Dopamine / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000378:metabolism; D013462:Sulfur Radioisotopes; D013997:Time Factors
D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D011994:Recombinant Proteins; D013462:Sulfur Radioisotopes; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; C045971:UH 232; D002069:Butaclamol; D008090:Lisuride; C039667:bromerguride; D003024:Clozapine; D006220:Haloperidol; D002118:Calcium; D004298:Dopamine